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S U M M A R Y
Background: Nosocomial infections caused by carbapenem-resistant Acinetobacter spp are a global health
problem. The aim of this study was to investigate the molecular epidemiology and the genetic support of
carbapenem resistance in Acinetobacter spp clinical isolates recovered from three different hospitals in
western Algeria from 2008 to 2012.
Methods: A total of 113 Acinetobacter spp isolates were identiﬁed by matrix-assisted laser desorption
ionization-time of ﬂight (MALDI-TOF) mass spectrometry. Antimicrobial susceptibility testing was
carried out, and minimum inhibitory concentrations (MICs) were determined by the dilution method on
Mueller–Hinton agar for b-lactams, aminoglycosides, ﬂuoroquinolones, and colistin. The characteriza-
tion of b-lactamases was investigated by phenotypic tests for the detection of metallo-b-lactamases and
oxacillinases. Resistance genes were screened for by quantitative PCR and sequenced when positive.
Results: Among the 113 isolates, 80 (70.8%) were found to be resistant to imipenem with MICs ranging
from 64 to 512 mg/ml. The blaOXA23like gene was detected in 50% (40/80) of the isolates and the
blaOXA24like gene was detected in 21.2% (17/80) of the isolates. In addition, the metallo-b-lactamase
blaNDM-1like was detected in ﬁve isolates (6.2%).
Conclusions: This study represents the ﬁrst description of autochthonous Acinetobacter spp producing
metallo-b-lactamase blaNDM-1like and oxacillinases blaOXA23like and blaOXA24like in western Algeria.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acinetobacter spp are major nosocomial pathogens. The genus
currently consists of more than 40 species, including validly
published species and genomic species.1 Of these, Acinetobacter
baumannii is the most clinically relevant Acinetobacter species. It
has emerged as a major cause of healthcare-associated infections
including pneumonia, urinary tract infection, and septicemia.2 It
has the ability to develop resistance to multiple classes of useful
antimicrobial agents.3 Closely related species, Acinetobacter
nosocomialis (formerly named Acinetobacter genomic species
(gen. sp.) 13TU) and Acinetobacter pittii (formerly named Acine-
tobacter gen. sp. 3), have also been associated with nosocomial
infections and outbreaks.4 These three clinically important species
are phenotypically and genotypically difﬁcult to differentiate, thus* Corresponding author. Tel.: +33 4 91 32 43 75; fax: +33 4 91 38 77 72.
E-mail address: jean-marc.rolain@univ-amu.fr (J.-M. Rolain).
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http://dx.doi.org/10.1016/j.ijid.2013.02.024they are grouped together into the Acinetobacter calcoaceticus–
Acinetobacter baumannii (ACB) complex.1 They are so much alike
that they cannot be differentiated using routine commercial
systems. Genotypic methodologies can be used to differentiate
them, such as the determination of speciﬁc gene sequences,
including the 16sRNA, recA, rpoB, and gyrB genes, in combination
with the technology of matrix-assisted laser desorption ionization-
time of ﬂight (MALDI-TOF) mass spectrometry (MS).5
The efﬁcacy of carbapenems against multidrug-resistant
Acinetobacter spp has been undermined by the emergence of
Ambler class B and class D carbapenemase-hydrolyzing b-
lactamases.6 The class D carbapenemase (oxacillinase) found in
A. baumannii can be clustered into four distinct groups: OXA–23-
like (OXA–23, OXA–27 and OXA–49), OXA–24-like (OXA–24/40,
OXA–25, OXA–26 and OXA–72), OXA–58-like (OXA–58 and OXA–
96), and OXA–51-like enzymes.7 The last group constitutes a
family of chromosomal enzymes typically present in A. baumannii.8
The high-level carbapenem resistance due to the expression of
genes encoding the class D carbapenemases, requires a strongses. Published by Elsevier Ltd. All rights reserved.
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ISAba1.9 This is characteristic of A. baumannii, and most outbreaks
of carbapenem-resistant A. baumannii associated with blaOXA23
have been identiﬁed using primers based on ISAba1.6
The new metallo-b-lactamase (MBL), New Delhi metallo-b-
lactamase 1 (NDM-1), was initially reported in Klebsiella pneumo-
niae clinical isolates from a Swedish patient who had previously
been hospitalized in India.10 Recently, cases of NDM-producing A.
baumannii have been described in several countries worldwide,
including Canada, USA, Sweden, UK, Austria, Belgium, France,
Netherlands, Germany, Japan, Africa, Oman, and Australia.11,12 At
present, the worldwide caseload is probably being driven by
people infected or colonized in the Indian subcontinent before
traveling elsewhere. However, there is already evidence of others
reservoirs of infected patients in the Balkan states, the Middle East,
and Israel, suggesting that the gene may become endemic
worldwide, similar to the blaKPC gene, which is now endemic in
Greece and Israel.13,14
In the present study, we evaluated the prevalence of antibiotic
resistance and the genetic background of carbapenem resistance in
a series of 113 A. baumannii strains isolated in western Algeria
between October 2008 and April 2012. We report ﬁve blaNDM-1-
positive A. baumannii strains recovered from autochthonous cases
in the same area.
2. Materials and methods
Bacterial isolates of Acinetobacter spp were recovered from
three different hospitals situated in north-western Algeria
(Tlemcen, Oran, and Sidi Bel Abbes). All of them were isolated
from the hospital environment and patients admitted to the
intensive care unit (ICU) and hematology, surgery, and neurosur-
gery wards, during the study period of October 2008 to April 2012.
They were identiﬁed using MALDI-TOF MS, which was performed
with a Bruker Daltonics Microﬂex (Bremen, Germany) using 96-
spot polished-steel targets.
Antimicrobial susceptibility was determined by disk diffusion
and agar dilution methods, in accordance with the Comite´ de
l’Antibiogramme de la Socie´te´ Franc¸aise de Microbiologie (CA-SFM)
2008 guidelines. Antibiotic disks were purchased from Bio-Rad
(Marnes-la-Coquette, France). The minimum inhibitory concentra-
tions (MICs) were determined by agar dilution method in Mueller–
Hinton medium (Fluka BioChemika, Spain) and E-test strips for
carbapenems (imipenem, meropenem) (bioMe´rieux, Marcy l’Etoile,
France). Isolates with MICs of imipenem >8 mg/ml and inhibition
zone diameter <17 mm were investigated in this study. The double-
disk synergy test (DDST) was used to detect MBL.
Strains showing non-susceptibility to carbapenems were
screened for the production of acquired carbapenem-hydrolyzing
class D b-lactamase: blaOXA23, blaOXA24, blaOXA58, intrinsic b-
lactamase blaOXA51, and MBL blaNDM-1. Quantitative real-time PCR
(CFX96, C1000 Thermal Cycler, Bio-Rad) and standard PCR were
carried out to detect the encoding genes. MasterMix was prepared
in accordance with the manufacturer’s instructions and positive
controls carrying each gene were used to determine the efﬁcacy of
the real-time PCR assay. The experimental run protocol used was
as follows: denaturation program (95 8C for 15 min), ampliﬁcation
and quantiﬁcation programs repeated 35 times (95 8C for 30 s,
60 8C for 1 min). Samples were considered positive if a threshold
cycle was reached during the 35 cycles or less. Standard PCR
analysis was performed for blaVIMlike, blaGIMlike, blaIMPlike,
blaKPClike, blaNDM-1like, blaCTX-Mlike, blaSHVlike, blaTEMlike, bla-
PERlike, and blaGESlike. PCR screening was also performed for
aminoglycoside-modifying enzyme and ﬂuoroquinolone resis-
tance genes (aac(3)-Ia, aac(60)-Ib, aadA, ant(20 0)-I, aph(30)-VI, armA,
rmtA, rmtF, arr-2, qnrA, and qnrB). Oligonucleotide primers andprobes used are listed in the Supplementary Material (Table S1).
Puriﬁed PCR products were sequenced using BigDye terminator
chemistry on an automated ABI 3730 sequencer (PE Applied
Biosystems, Foster City, CA, USA) based on Sanger’s sequencing
method. Data collection and analysis were performed using
CodonCode Aligner 3.7.1.1 sequencing analysis software.
3. Results
In total, 100 human isolates and 13 hospital environment
isolates were collected from Tlemcen Hospital, Oran Hospital, and
Sidi Bel Abbes Hospital (51, 45, and 17, respectively). Overall, 106
strains were identiﬁed as A. baumannii, one strain as A. radio-
resistens (from Sidi Bel Abbes Hospital), two strains as A.
nosocomialis (from Oran Hospital), and four strains as A. pittii
(from Tlemcen, Oran, and Sidi Bel Abbes hospitals). All the isolates
were identiﬁed to the species level with a log score >2.0; the mass
spectrometry-based identiﬁcation scheme yielded identical results
compared against the default Bruker database. A mean spectra
projection (MSP) dendrogram was generated on the basis of
consensus spectra obtained from each bacterium (Figure 1).
The overall susceptibility of all the strains according to the
French CA-SFM breakpoints showed that most of the isolates were
characterized by resistance to b-lactams (piperacillin 92.2%,
piperacillin–tazobactam 88%, ticarcillin 95.9%, ticarcillin–clavula-
nic acid 96.2%, ceftazidime 98.6%), to ﬂuoroquinolones (ciproﬂox-
acin 85%, with MICs ranging from 0.125 to 0.25 mg/ml), and to
aminoglycosides (amikacin 79.1%, gentamicin 56.1%, and tobra-
mycin 38.9%, with MICs ranging from 1 to 512 mg/ml), whilst they
differed in their susceptibility to imipenem (70.8%) and showed
different levels of resistance with MICs ranging from 0.5 to 512 mg/
ml. However, all isolates were susceptible to colistin (MIC 0.125–
0.25 mg/ml) (Table 1).
Eighty imipenem-resistant strains (with MIC ranging from 64 to
512 mg/ml), including 42 (82%) imipenem-resistant A. baumannii
from Tlemcen Hospital, 31 (69%) imipenem-resistant Acinetobacter
spp from Oran Hospital (30 A. baumannii and one A. nosocomialis),
and seven (41%) imipenem-resistant Acinetobacter spp from Sidi
Bel Abbes Hospital (six A. baumannii and one A. radioresistens) were
screened for the presence of carbapenemase-encoding genes
(Table 2). Real-time PCR results showed that 40 out of 80
imipenem-resistant isolates were positive for the blaOXA23 gene
(31 A. baumannii from Tlemcen Hospital, seven A. baumannii and
one A. nosocomialis from Oran Hospital, and one A. baumannii from
Sidi Bel Abbes Hospital) and 17 isolates harbored the blaOXA24
gene (four A. baumannii from Tlemcen Hospital, 11 A. baumannii
from Oran Hospital, and one A. baumannii and one A. radioresistens
from Sidi Bel Abbes Hospital), of which ﬁve coexisted with the
OXA–23 gene (Table 3).
In addition, among all the isolates, ﬁve from Oran were positive
for the MBL NDM-1. All ﬁve isolates showed positivity by DDST. The
gene was sequenced and revealed 99% identity to the sequence
reported in the GenBank database under accession number
JQ739157.1. The ﬁve NDM-1-positive isolates were from autochtho-
nous cases in ﬁve patients admitted to the ICU and hematology wards
of Oran Hospital. All ﬁve blaNDM-1-positive isolates were identiﬁed as
A. baumannii. The earliest positive isolate was collected in April 2011
from a 38-year-old man hospitalized on the hematology ward who
was then transferred to the ICU of Oran Hospital for a severe cranial
trauma subsequent to a stair fall. He had no relevant travel history
and neither did his family. Antibiotics used were ceftazidime,
amikacin, and colistin, then imipenem and colistin. The patient died
in July 2011. The four other patients were all men aged up to 38 years
who were admitted to the same ICU as the ﬁrst patient during the
period April to August 2011. Unfortunately no additional clinical
records were available for these patients.
Figure 1. Mean spectra projection (MSP) dendrogram generated by BIOTYPER software (version 2; Bruker Daltonics) of Acinetobacter spp strains.
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blaTEMlike, blaPERlike blaGESlike, blaKPClike, or blaOXA58 were
detected in the collected strains. Resistance to aminoglycosides
(gentamicin, tobramycin, and amikacin) observed in almost all the
isolates was due to the expression of aac(3)-Ia (77 isolates), aadA
(57 isolates), ant(20 0)-I (60 isolates), aph(30) (70 isolates), and
aac(60)-Ib (one isolate) genes. No isolates were positive for rmtA,
rmtF, armA, arr-2, or the qnr genes.
4. Discussion
Acinetobacter spp has recently emerged as one of the
most important opportunistic nosocomial pathogens. AlthoughTable 1
Resistance rates for Acinetobacter spp isolates in this study
Antimicrobial agent Resistance rate (%)
Tlemcen (n = 51) Oran 
Piperacillin 94.1 95.5 
Piperacillin–tazobactam 84.3 91.0 
Ticarcillin 98.0 97.7 
Ticarcillin–clavulanic acid 100.0 97.7 
Ceftazidime 98.0 100.0 
Imipenem 78.0 71.0 
Meropenem 84.0 77.7 
Gentamicin 50.9 26.6 
Tobramycin 23.0 57.7 
Amikacin 82.3 71.0 
Ciproﬂoxacin 88.2 91.0 
Colistin 0.0 0.0 A. baumannii is the most important species in clinical settings, the
other Acinetobacter spp, such as A. pittii and A. nosocomialis, are also
frequently isolated in hospitals and have been involved in a
number of outbreaks in ICUs.3 The analysis of the dendrogram
generated by BIOTYPER software showed that the protein
signatures formed ﬁve separate clusters related to each one of
the species, excluding A. baumannii strains that form two separates
clusters. This is consistent with the ﬁndings of Espinal et al., who
showed that MALDI-TOF MS is able to identify and class
Acinetobacter strains in separate clusters.5
In our study, we investigated the high prevalence of carbape-
nemase-encoding genes (OXA-type carbapenemase and blaNDM-1)














Isolates of Acinetobacter spp in relation to the presence of carbapenemase enzymes
Carbapenemases Hospital location Species No. of isolates Samples
OXA–51 OXA–23 OXA–24 OXA–58 NDM
+ + +   Tlemcen A. baumannii 4 Tracheal aspirate, rectal swab, urine,
environment
Oran A. baumannii 1 Tracheal aspirate
Sidi Bel Abbes - 0 -
+ +    Tlemcen A. baumannii 27 Tracheal aspirate, rectal swab, urine,
wound environment
Oran A. baumannii (n = 6)
A. nosocomialis (n = 1)
7 Wound, tracheal aspirate
Sidi Bel Abbes A. baumannii 1 Wound, environment
+  +   Tlemcen - 0 -
Oran A. baumannii 10 Urine, tracheal aspirate
Sidi Bel Abbes A. baumannii (n = 1)
A. radioresistens (n = 1)
2 Tracheal aspirate
+     Tlemcen A. baumannii (n = 13)
A. pittii (n = 1)
14 Tracheal aspirate, environment, urine
Oran A. baumannii (n = 8)
A. pittii (n = 1)
9 Tracheal aspirate, urine
Sidi Bel Abbes A. baumannii (n = 5)
A. pittii (n = 1)
6 Tracheal aspirate
+    + Tlemcen - 0 -
Oran A. baumannii 5 Urine
Sidi Bel Abbes - 0 -
     Tlemcen - 0 -
Oran A. nosocomialis 1 Urine
Sidi Bel Abbes A. pittii 1 Wound
Table 3
Distribution of carbapenem-encoding genes in the three hospitals
No. of imipenem-resistant OXA–23 (%) OXA–24 (%) OXA–58 (%) NDM-1 (%)
Tlemcen (n = 42) 31 (74.0%) 4 (9.5%) 0 (0%) 0 (0%)
Oran (n = 31) 8 (25.8%) 11 (35.4%) 0 (0%) 5 (16.0%)
Sidi Bel Abbes (n = 7) 1 (14.0%) 2 (28.0%) 0 (0%) 0 (0%)
Total (n = 80) 40 17 0 5
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America, Asia Oceania, and Africa.11,15,16 There is a worldwide
variation in the rate of carbapenem resistance of A. baumannii from
one geographical area to another.12 In Algeria, the dissemination of
OXA–23 carbapenemases among A. baumannii isolates has also
been reported since 2010.15–17 In our series of isolates, the main
molecular support explaining the resistance to carbapenems is the
presence of blaOXA23 carbapenemase-encoding genes, along with
the coexistence of blaOXA24. Consequently, the isolates demon-
strated high rates of co-resistance to all other classes of
antimicrobial agents tested. A limited number of antimicrobial
agents maintain reliable levels of activity against OXA–23-
producing A. baumannii.18 Neither of the non-baumannii Acineto-
bacter showed the coexistence of blaOXA23 with blaOXA24, in
contrast to A. baumannii isolates, of which ﬁve harbored both genes
at the same time.
OXA–23 (formerly ARI-1) was originally reported in an A.
baumannii detected in Scotland in 1985.19 In a report by Opazo
et al., the blaOXA23 gene is reported to have originated in the
chromosome of A. radioresistens, which might be the natural
reservoir of these enzymes20 that are currently emerging as the
sources of carbapenem resistance in A. baumannii worldwide.21
Although OXA–58 has previously been detected in Tlemcen and
Annaba hospitals,16,22 none of the isolates in this series were
positive for this gene. The blaOXA51-like gene, originally intrinsic to
A. baumannii, was detected in all the isolates except one A. pittii and
one A. nosocomialis. These blaOXA51-like genes, all preceded by
ISAba1, may confer a high level of carbapenem resistance. They
were probably located on plasmids that might have emergedbetween different clones of non-baumannii Acinetobacter species
and also between A. baumannii clones. The plasmid-borne ISAba1–
blaOXA51-like in non-baumannii Acinetobacter species not only
contributes to a high level of carbapenem resistance, but also
affects the accuracy of using blaOXA51-like detection as a tool for
differentiating A. baumannii from other Acinetobacter species.23
In the present study, we found ﬁve strains producing the
blaNDM-1 gene in autochthonous cases in the ICU of Oran Hospital
between April and August 2011. No bacterial isolates harboring the
blaNDM-1 gene were detected in Algeria from the beginning of the
study (2008) until this period. The global distribution of the
blaNDM-1 gene has been extensively described.
24 It has been found
in diverse isolates since it was ﬁrst discovered in K. pneumoniae in
2008.10 The potential presence of this gene in non-baumannii
Acinetobacter should receive proper attention. All ﬁve of the
blaNDM-1-positive isolates were identiﬁed as A. baumannii, suggest-
ing that this species, which has a robust survival capability, can
easily acquire foreign resistance genes.25 NDM-1-producing A.
baumannii has already been described in two Algerian patients. The
patients were hospitalized in Oran ICU and transferred to French26
and Belgian27 hospitals. Patient histories were conﬁrmed as
lacking any foreign travel, suggesting that NDM-producing A.
baumannii isolates may have already spread in North Africa.26,27
Reports describing NDM-type carbapenemase-producers isolated
from patients previously hospitalized in high-prevalence countries
is increasing.28 However, the geographic origin and the time of the
ﬁrst appearance of this gene are unknown.12 A recent study has
suggested that the putative original source of the blaNDM-1 gene
could be from the chromosome of plant pathogens, such as
E. Mesli et al. / International Journal of Infectious Diseases 17 (2013) e739–e743 e743Pseudoxanthomonas and related bacteria widespread in the
environment.29 The spread of strains carrying the blaNDM-1 gene
will enhance the likelihood of variants emerging. Interestingly, we
have evidence that NDM-encoding genes may be widespread in A.
baumannii, and further molecular surveys will be necessary to
evaluate their distribution in that species. Many studies have
constituted reports on carbapenem-resistant A. baumannii whose
carbapenem resistance is mediated mainly by OXA-type carbape-
nemases. Despite being less commonly identiﬁed in A. baumannii
than oxacillinase, NDM-1 is currently spreading worldwide and
could be reported with a high frequency as a mediator of
carbapenem resistance. It is thus critical to survey the presence
of this gene in multidrug-resistant (MDR) A. baumannii isolates
worldwide.
Although polymyxins such as colistin (polymyxin E) have not
typically been included in regimens to treat Acinetobacter
infections because of their neurotoxicity and nephrotoxicity, they
are now considered as one of the last resorts against MDR
Acinetobacter infections. Owing to the increasing use of colistin
against Gram-negative pathogens and the high recombination rate
of Acinetobacter spp, it is of concern that colistin resistance in
Acinetobacter spp isolates may increase rapidly.30
In conclusion, the spread of NDM-1-positive A. baumannii
isolates in the hospital setting reemphasizes the need for strict
adherence to surveillance programs in order to prevent the
colonization, the infection, and the dissemination of this gene in
Algeria.
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